Mounjaro vs Wegovy: What’s the Difference and Which Is Better? Onlinepharmaustralia Mounjaro and Wegovy are two prescription medicines that have attracted significant attention for weight management. Both can help eligible patients lose weight when used alongside a reduced-calorie diet and increased physical activity, but they are not the same medicine.
Mounjaro contains tirzepatide, while Wegovy contains semaglutide. They work through different but related hormonal pathways, have different dosing schedules and can have different side effects and suitability depending on the individual.
So, is Mounjaro better than Wegovy?
There is no single answer for everyone. The appropriate treatment depends on your health, medical history, treatment goals, other medicines, response to treatment and advice from your healthcare professional.
This guide explains the key differences between Mounjaro and Wegovy for patients in Australia.
Mounjaro vs Wegovy at a Glance
| Feature | Mounjaro | Wegovy |
|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide |
| Main hormone pathways | GIP and GLP-1 receptors | GLP-1 receptor |
| Administration | Once weekly injection | Once weekly injection |
| Used for weight management | Yes, when prescribed appropriately | Yes, when prescribed appropriately |
| Used for type 2 diabetes | Yes | Product indication differs; check current Australian product information |
| Dose escalation | Gradual | Gradual |
| Common side effects | Nausea, diarrhoea, vomiting, constipation and other gastrointestinal effects | Nausea, diarrhoea, vomiting, constipation and other gastrointestinal effects |
Always check the current Australian Product Information and Consumer Medicine Information because approved indications, presentations and prescribing information can change.
What Is Mounjaro?
Mounjaro contains tirzepatide, a medicine that activates both GIP and GLP-1 receptors.
These are hormone pathways involved in appetite regulation, glucose control and other metabolic processes.
For appropriate adults, Mounjaro may be prescribed as part of treatment for chronic weight management alongside a reduced-calorie diet and increased physical activity.
It is also used in the treatment of type 2 diabetes.
Mounjaro is administered once weekly.
What Is Wegovy?
Wegovy contains semaglutide, a GLP-1 receptor agonist.
It works primarily through the GLP-1 pathway and can influence appetite, food intake and glucose regulation.
Wegovy is prescribed for chronic weight management in eligible patients as part of a broader treatment plan that includes dietary and physical-activity measures.
It is also administered once weekly.
How Are Mounjaro and Wegovy Different?
The biggest pharmacological difference is how the two medicines work.
Mounjaro targets two pathways
Tirzepatide activates:
- GIP receptors
- GLP-1 receptors
Wegovy targets one pathway
Semaglutide activates:
- GLP-1 receptors
This difference is one reason researchers have investigated whether tirzepatide and semaglutide produce different average weight-loss outcomes.
However, clinical trial results should not be interpreted as a guarantee of what one individual will experience.
Which Causes More Weight Loss: Mounjaro or Wegovy?
Clinical trials have found substantial weight loss with both medicines.
In the SURMOUNT-1 trial, adults with obesity or overweight and at least one weight-related condition who received tirzepatide experienced substantial average weight reduction over 72 weeks.
At the highest studied dose, the average reduction in body weight was approximately 20.9%.
Semaglutide has also produced substantial average weight loss in clinical trials.
In the STEP 1 trial, adults with overweight or obesity receiving once-weekly semaglutide 2.4 mg experienced an average body-weight reduction of approximately 14.9% after 68 weeks.
These numbers are useful for understanding clinical trial outcomes, but they should not be interpreted as a prediction for an individual patient.
Different studies also have different designs, populations, treatment durations and eligibility criteria.
Is Mounjaro More Effective Than Wegovy?
Direct comparisons are more useful than comparing results from completely separate studies.
The SURMOUNT-5 trial directly compared tirzepatide with semaglutide in adults with obesity without diabetes.
After the study period, tirzepatide produced greater average weight loss than semaglutide in that trial.
However, “more effective on average” does not mean that Mounjaro is automatically the right medicine for every person.
A patient’s medical history, tolerability, other medicines, contraindications, treatment goals and response all need to be considered.
Mounjaro vs Wegovy: How Do They Affect Appetite?
Both medicines can reduce appetite.
This can make it easier for some patients to maintain a lower calorie intake.
Mounjaro and Wegovy should not be thought of simply as appetite suppressants, however. Their effects involve complex hormonal pathways affecting appetite, food intake and metabolic regulation.
Individual responses vary.
Some people experience a substantial reduction in appetite, while others experience a more moderate effect.
Mounjaro vs Wegovy Side Effects
Both medicines can cause gastrointestinal side effects.
Common effects can include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort
- Reduced appetite
Side effects can become more noticeable when treatment is started or when the dose is increased.
Many gastrointestinal adverse effects are mild to moderate and may improve with time, but persistent or severe symptoms should be discussed with a healthcare professional.
Which Has Fewer Side Effects?
There is no simple answer.
Both tirzepatide and semaglutide can cause gastrointestinal adverse effects, and individual tolerability varies.
One person may tolerate Mounjaro well while another experiences significant nausea. The same is true for Wegovy.
The appropriate medicine is therefore not necessarily the one with the lowest average rate of a particular side effect. Your individual response matters.
Mounjaro vs Wegovy: Dosing
Both medicines use gradual dose escalation.
This is important because starting at a higher dose does not necessarily produce better results and may increase the likelihood of adverse effects.
For Mounjaro, the Australian dosing schedule generally begins at 2.5 mg once weekly before increasing to 5 mg after four weeks, with further increases considered when clinically appropriate.
Wegovy also uses a gradual escalation schedule before reaching its maintenance dose.
Do not compare the milligram amounts directly.
For example, 5 mg of tirzepatide is not equivalent to 5 mg of semaglutide.
They are different active ingredients with different pharmacology.
Which One Works Faster?
Neither medicine should be judged by the first few days of treatment.
Both are introduced gradually, and meaningful weight change develops over time.
Some patients notice appetite changes relatively early, while measurable weight loss can take longer.
The initial treatment period is also partly about determining how well the medicine is tolerated.
Avoid increasing your dose simply because you have not seen rapid weight loss.
Mounjaro vs Wegovy for Type 2 Diabetes
Mounjaro is used in the treatment of type 2 diabetes.
Wegovy is primarily positioned as a weight-management product, while semaglutide is also available in other products and formulations for diabetes treatment.
Patients with type 2 diabetes should not switch between medicines without medical supervision.
Your healthcare professional can consider your blood glucose control, current diabetes medicines, weight-management goals and other health factors.
Mounjaro vs Wegovy for Weight Management
Both medicines may be considered as part of a medical weight-management programme for eligible patients.
Medication is only one component of treatment.
A comprehensive programme may also involve:
- Nutrition
- Physical activity
- Behavioural changes
- Sleep
- Medical monitoring
- Management of obesity-related conditions
- Regular follow-up
The goal is not simply to produce rapid weight loss but to support sustainable improvements in health.
Can You Switch From Wegovy to Mounjaro?
Some patients may be able to switch from one medicine to another, but this should be decided by a healthcare professional.
Do not independently stop one medicine and start the other.
Your doctor may need to consider:
- Your current dose
- How long you have been taking the medicine
- Side effects
- Weight response
- Blood glucose control
- Other medications
- Medical history
- Any contraindications
There is no universal conversion between Mounjaro and Wegovy doses.
Can You Take Mounjaro and Wegovy Together?
Mounjaro and Wegovy should not be combined unless specifically directed by an appropriately qualified healthcare professional.
Both medicines affect incretin-related pathways and can cause gastrointestinal adverse effects.
Using two weight-management medicines together without medical supervision could increase risks without providing an established benefit.
If your current treatment is not working as expected, discuss alternatives with your healthcare professional rather than adding another medicine yourself.
Mounjaro vs Wegovy and Diet
Neither medicine replaces a balanced diet.
A suitable eating pattern can help support treatment and may also improve tolerability.
People experiencing nausea may find that smaller meals, slower eating and avoiding very large or heavy meals are helpful.
A nutritious diet should generally include appropriate amounts of:
- Protein
- Vegetables
- Fruit
- Whole grains
- Healthy fats
- Fluids
Individual nutritional needs vary, particularly for people with diabetes or other medical conditions.
Read our related guide:
Mounjaro Diet Plan: What to Eat and Foods to Avoid
Mounjaro vs Wegovy and Exercise
Physical activity remains an important part of weight management.
Australian adult physical-activity guidelines recommend working toward 150 to 300 minutes of moderate-intensity activity each week, or 75 to 150 minutes of vigorous activity, together with muscle-strengthening activities on at least two days each week.
Your appropriate exercise level depends on your health and fitness.
People experiencing significant nausea, vomiting, diarrhoea or weakness may need to modify their activity and address hydration before exercising.
What Happens When You Stop Mounjaro or Wegovy?
Weight management does not necessarily end when medication is stopped.
Research with both tirzepatide and semaglutide demonstrates that weight regain can occur after treatment withdrawal.
This is one reason chronic weight management should be approached as an ongoing health issue rather than a short-term diet.
If you are considering stopping treatment, speak with your healthcare professional about what happens next.
Do not stop prescription treatment simply because you have reached a target weight without discussing the plan with your healthcare team.
Who Should Take Mounjaro or Wegovy?
Neither medicine is appropriate for everyone.
A healthcare professional may consider factors such as:
- Body mass index and weight-related health risks
- Type 2 diabetes
- Current medicines
- Medical history
- Previous weight-management treatments
- Pregnancy or plans to become pregnant
- Gastrointestinal conditions
- Previous reactions to related medicines
- Individual treatment goals
Eligibility should be determined through an appropriate medical assessment.
Which Is Better: Mounjaro or Wegovy?
There is no universal winner.
Clinical evidence suggests that tirzepatide can produce greater average weight loss than semaglutide in certain direct-comparison settings.
However, the best treatment for an individual patient depends on much more than average trial weight loss.
A suitable choice may depend on:
- Your medical history
- Your treatment goals
- Other medicines
- Side-effect tolerance
- Diabetes status
- Previous treatment response
- Cost and availability
- Your healthcare professional’s assessment
The medicine with the highest average weight-loss result is not automatically the safest or most appropriate choice for every patient.
Mounjaro vs Wegovy: Frequently Asked Questions
Is Mounjaro the same as Wegovy?
No. Mounjaro contains tirzepatide, while Wegovy contains semaglutide. They are different prescription medicines.
Which is stronger, Mounjaro or Wegovy?
Direct clinical evidence indicates greater average weight loss with tirzepatide than semaglutide in a head-to-head obesity trial. However, individual results vary and the medicines should not be considered interchangeable.
Which causes more weight loss?
Both can produce substantial weight loss. In direct clinical comparison, tirzepatide produced greater average weight reduction than semaglutide in the studied population.
Can I switch from Wegovy to Mounjaro?
Some patients may be able to switch, but this should be planned with a healthcare professional. There is no simple milligram-for-milligram conversion.
Can I take Mounjaro and Wegovy together?
Do not combine them unless specifically instructed by your healthcare professional.
Which has fewer side effects?
Both can cause gastrointestinal side effects. Individual tolerability varies, so there is no universal answer.
Can Mounjaro and Wegovy both be used for weight loss?
Both have roles in medical weight management for eligible patients, subject to their approved indications and individual medical circumstances.
Do Mounjaro and Wegovy work immediately?
Neither should be expected to produce dramatic weight loss immediately. Treatment is introduced gradually and results develop over time.
Do you regain weight after stopping Mounjaro or Wegovy?
Weight regain can occur after stopping treatment. Your healthcare professional can help develop an appropriate long-term weight-management strategy.
The Bottom Line
Mounjaro and Wegovy are different medicines that can both play a role in medical weight management.
Mounjaro contains tirzepatide and activates both GIP and GLP-1 receptors, while Wegovy contains semaglutide and acts primarily through the GLP-1 receptor.
Clinical evidence indicates that tirzepatide can produce greater average weight loss than semaglutide in some direct comparisons. However, treatment decisions should not be based on weight loss percentages alone.
The right medicine depends on the individual patient, including medical history, treatment goals, other medicines, tolerability and clinical assessment.
If you are considering Mounjaro, Wegovy or a change in weight-management treatment, speak with an appropriately qualified healthcare professional.
This article is for educational purposes and does not replace the current Australian Product Information, Consumer Medicine Information or personalised medical advice.